This review aims to highlight the applications of one of the most prominent optical biosensor technologies, surface plasmon resonance (SPR), in the drug discovery process and quality analysis of pharmaceutical compounds and their particularities. SPR assay formats and experimental issues are used for pharmacokinetic drug profiling, ADMET studies, high-throughput screening, and fragment-based drug screening, the last with an emphasis on the detection of small (drug) molecules. The classical method strengths and some applications of localized SPR and SPR imaging that are of high interest in the drug discovery process are presented, as well as possible challenges. While similar works treat separately the steps of drug discovery or focus only on the detection of drug residues in food or health safety, this review presents in a compact format the results and the progress obtained in both areas (drug discovery and quality analysis) based on the application of SPR biosensors.

This review summarizes scientific research activity on biosensors, especially screen-printed, electrode-based biosensors. The basic configurations of biosensors based on screen-printing technology are discussed and different procedures for immobilization of the biorecognition component are reviewed. Theoretical aspects are exemplified by practical environmental and food-analysis applications of screen-printed, electrode-based biosensors.

No abstract

In this paper we review the underlying principles of the surface plasmon resonance (SPR) technique, particularly emphasizing its advantages along with its limitations regarding the ability to discriminate between the specific binding response and the interfering effects from biological samples. While SPR sensors were developed almost three decades, SPR detection is not yet able to reduce the time-consuming steps of the analysis, and is hardly amenable for miniaturized, portable platforms required in point-of-care (POC) testing. Recent advances in near-field optics have emerged, resulting in the development of SPR imaging (SPRi) as a powerful optical, label-free monitoring tool for multiplexed detection and monitoring of biomolecular events. The microarrays design of the SPRi chips incorporating various metallic nanostructures make these optofluidic devices more suitable for diagnosis and near-patient testing than the traditional SPR sensors. The latest developments indicate SPRi detection as being the most promising surface plasmon-based technique fulfilling the demands for implementation in lab-on-a-chip (LOC) technologies.

Graphite electrodes fabricated by screen-printing have been used as amperometric detectors in biosensors based on NAD(+)-dependent dehydrogenases, tyrosinase, or genetically modified acetylcholinesterases. The mono-enzyme sensors have been optimized as disposable or reusable devices for detection of a variety of substrates important in the food industry ( D-lactic acid, L-lactic acid, acetaldehyde) or in environmental pollution control (phenols and dithiocarbamate, carbamate and organophosphorus pesticides). The sensors were prepared in four configurations differing in enzyme confinement, enzyme immobilization and location of the immobilization agent in the biosensor assembly. Tests on real samples have been performed with the biosensors; D-lactic acid and acetaldehyde have been detected in wine and phenols in air.